ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Edmunds, L. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Edmunds, L. H., Jr

Ann Thorac Surg 1998;66:S12-S16
© 1998 The Society of Thoracic Surgeons

Inflammatory response to cardiopulmonary bypass

L. Henry Edmunds, Jr, MDa

a Division of Cardiothoracic Surgery, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA

Address reprint requests to Dr Edmunds, Division of Cardiothoracic Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA 19104

Presented at "Risk Management in CABG: Significant Surgical Considerations," New Orleans, LA, Jan 24, 1998.


   Abstract
Top
 Abstract
Introduction
 The contact system
 Complement
 Neutrophil activation
 Monocytes
 Vasoactive substances associated...
 Inhibiting the inflammatory...
 References
 
This article reviews the roles of the contact and complement systems and of neutrophils and monocytes in the inflammatory response to cardiopulmonary bypass and open heart operation. These blood proteins and cells, together with other blood elements, produce the vasoactive and cytotoxic substances and microemboli that cause the morbidity associated with cardiopulmonary bypass and open heart operation.


   Introduction
Top
 Abstract
 Introduction
The contact system
 Complement
 Neutrophil activation
 Monocytes
 Vasoactive substances associated...
 Inhibiting the inflammatory...
 References
 
Kallikrein is produced by the contact system of plasma proteins and directly mediates neutrophil activation; complement is separately activated by both the classic and alternative pathways. Complement activation produces three anaphylatoxins, powerful vasoactive substances, and the terminal complement complex that lyses cells. Monocytes also are activated during cardiopulmonary bypass (CPB) and open heart operation, in both the wound and the perfusion circuit. Monocytes are very strongly procoagulant and express tissue factor (TF), which initiates the extrinsic coagulation pathway. They also produce numerous proinflammatory and antiinflammatory cytokines, with plasma concentrations of nearly all peaking several hours after CPB. A very large number of vasoactive substances are produced during CPB and open heart operation; these substances cause edema, decreased myocardial contractility, and changes in vascular resistance in various vascular beds. Preventing or attenuating activation of these blood elements during open heart operation offers a means of substantially reducing the morbidity associated with this technology.

Cardiopulmonary bypass is not possible without heparin, but it is not an ideal anticoagulant. The coagulation cascade is an amplification system in which one protease begets thousands of copies of the next protease, which then begets thousands more of the next enzyme in the chain. Heparin is not an ideal anticoagulant because it inhibits coagulation at the end of the coagulation cascade rather than at the beginning. Thus many powerful proteases are produced before heparin inhibits clot formation.

Cardiopulmonary bypass activates five plasma protein systems: contact, intrinsic coagulation, extrinsic coagulation, complement, and fibrinolytic (Table 1). Blood cells activated by CPB are platelets, neutrophils, monocytes, endothelial cells, and lymphocytes. Activation of these blood elements mediates the principal complications of CPB: bleeding, thromboembolism, fluid retention, and temporary organ dysfunction [1].


View this table:
[in this window]
[in a new window]
  		Table 1. Plasma Protein Systems and Blood Cells Activated by Cardiopulmonary Bypass

 
The inflammatory reaction principally involves four blood elements: the contact activation system, the complement system, neutrophils, and monocytes. Many nonblood variables affect the magnitude of the inflammatory response, including biomaterials in contact with blood, surface coatings, activation of some proteins by the operation itself, temperature, aortic cross-clamp time, myocardial reperfusion, steroids, antioxidants, and the use of various protease inhibitors that may attenuate the response. With respect to biomaterials, it should be noted that there is no such thing as a nonthrombogenic biomaterial; a biomaterial described as "thromboresistant" may cause clotting more slowly than other materials but does not prevent it. Like thromboresistance, "biocompatibility" is also an imprecise term that suggests some undefined advantage of one material over another.


   The contact system
Top
 Abstract
 Introduction
 The contact system
Complement
 Neutrophil activation
 Monocytes
 Vasoactive substances associated...
 Inhibiting the inflammatory...
 References
 
The contact system of plasma proteins consists of factor XII (Hageman factor), prekallikrein, high-molecular-weight kininogen, and factor XI. On negatively charged surfaces, factor XII is autoactivated and cleaves into two serine proteases, factor XIIa and factor XIIf. Factor XIIa activates factor XIa and initiates the intrinsic coagulation pathway. Factor XIIa also activates prekallikrein to form kallikrein and high-molecular-weight kininogen to form bradykinin [2]. Kallikrein is a major mediator that directly activates neutrophils and facilitates cleavage of factor XII in a feedback loop (Fig 1). Kallikrein cannot be measured directly, but is measured by measuring the kallikrein–C1 inhibitor complex. In vitro recirculation of heparinized fresh human blood demonstrates sharp increases in the kallikrein–C1 inhibitor complex and the C1–C1 inhibitor complex. C1 is the first protein in the complement system.



View larger version (17K):
[in this window]
[in a new window]
  		Fig 1. Factor XII (FXII) in the presence of prekallikrein and high-molecular-weight kininogen (HMWK) is cleaved into active fragments, FXIIa and FXIIf (fragments, not shown). FXIIa acting on FXI initiates the intrinsic coagulation cascade. Cleavage of HMWK produces bradykinin. Neutrophils are activated by kallikrein, complement, and other agonists; fibrinolysis is initiated by generation of thrombin, which stimulates production of tissue plasminogen activator by endothelial cells. Complement is not activated by contact system proteins. (HLE = human leukocyte elastage; TF = tissue factor.)

 

   Complement
Top
 Abstract
 Introduction
 The contact system
 Complement
Neutrophil activation
 Monocytes
 Vasoactive substances associated...
 Inhibiting the inflammatory...
 References
 
Complement is activated by both the classic and alternative pathways during CPB. The initial activation of blood in the nonendothelial cell perfusion circuit probably occurs by the classic pathway. However, a small amount of C3a formed by the classic pathway initiates activation of the alternative pathway that has a feedback loop. The classic pathway is also activated by the heparin–protamine complex when protamine is given. This causes a big spike in complement activation and is the most likely reason for hypotension coincidental with protamine in approximately 50% of patients.


   Neutrophil activation
Top
 Abstract
 Introduction
 The contact system
 Complement
 Neutrophil activation
Monocytes
 Vasoactive substances associated...
 Inhibiting the inflammatory...
 References
 
Complement has three anaphylatoxins, C3a, C4a, and C5a, which are powerful vasoactive substances. After C5a is produced, C5b forms the terminal complement complex (C5b through C9). Years ago, Craddock and coworkers [3] photographed the response of neutrophils when exposed to activated complement; within 20 seconds of exposure, docile neutrophils turn into very angry cells, expressing pseudopods and releasing granule contents (Fig 2). The neutrophil is the killer cell of the defense reaction and contains many cytotoxic enzymes: neutrophil elastase, cathepsin G, lysozymes, and myeloperoxidase. Neutrophil elastase is a powerful enzyme that, among other actions, has an important role in the development of emphysema, especially in smokers. Neutrophil elastase is released during open heart operation; levels of elastase increase during CPB and return toward baseline over 24 hours (Fig 3) [4]. Neutrophils also produce oxygen free radicals, hydrogen peroxide, and hypobromous acid; all are extremely cytotoxic. Activated complement and neutrophils both increase perivascular edema by directly attacking vein walls.



View larger version (68K):
[in this window]
[in a new window]
  		Fig 2. Activation of neutrophils by activated complement. (Reproduced from [3].)

 


View larger version (13K):
[in this window]
[in a new window]
  		Fig 3. Neutrophil counts and plasma levels of neutrophil lactoferrin and human neutrophil elastase during clinical cardiopulmonary bypass (CPB) are shown. Each point is the mean and standard error of the mean of 10 patients (a = before induction of anesthesia; b = after anesthesia, before heparin; c = after heparin, before CPB; d = 5 minutes after start of CPB; e = 45 minutes after start of CPB; f = just before CPB ended; g = 60 minutes after CPB; h = 24 hours after CPB.) (Reproduced from [4] with permission of Lippincott Williams & Wilkins.)

 
Although both complement and neutrophil activation are important, the neutrophil is the main target in efforts to control the inflammatory response associated with CPB and open heart operation. As noted above, there are many factors that can affect complement, and it does not remain in the circulation long after CPB ends. Neutrophils pose a major challenge and, unfortunately, we do not have a feasible way to inhibit neutrophil activation during open heart operation.


   Monocytes
Top
 Abstract
 Introduction
 The contact system
 Complement
 Neutrophil activation
 Monocytes
Vasoactive substances associated...
 Inhibiting the inflammatory...
 References
 
Monocytes also are activated in the inflammatory response. In an in vitro perfusion circuit monocytes appear to be activated more slowly than contact and complement proteins and neutrophils. When fresh, heparinized human blood is recirculated at 37° or 28°C in an in vitro system for up to 6 hours, monocyte expression of TF and the Mac-1 receptor is delayed (Fig 4) [5]. Monocytes attached to the tubing of the circuit are highly activated when studied at the end of 6 hours of recirculation. In a patient study, monocytes expressed TF and procoagulant activity in the wound promptly and without the delay observed in the in vitro perfusion circuit (Fig 5). Simultaneous blood samples obtained from blood around the heart and from the perfusion circuit showed that pericardial samples contained increased amounts of F1.2 (a marker of thrombin formation), activated factor VII, and monocytes that expressed TF as compared with perfusate samples [6].



View larger version (23K):
[in this window]
[in a new window]
  		Fig 4. Bar graph showing monocyte and lymphocyte surface Mac-1 fluorescence during simulated extracorporeal circulation. The expression of monocyte Mac-1 was measured by reactivity with monoclonal antibody LM2 to the ({alpha} chain of the leukocyte integrin Mac-1). Lymphocytes were negative. (R = recovered cells; SC = standing control cells.) (Reproduced from [5] with permission of Lippincott Williams & Wilkins.)

 


View larger version (16K):
[in this window]
[in a new window]
  		Fig 5. Tissue factor (TF) expressed by monocytes during and after cardiopulmonary bypass (CPB) and open heart operation. Values are the mean and standard error of the mean and represent the percentage of cells that express TF compared with monocytes maximally stimulated by lipopolysaccharide. Samples were taken after heparin infusion, before CPB; 30–45 minutes after start of CPB from the perfusate simultaneously with the pericardial blood sample; within 5 minutes after CPB; and 15 minutes after protamine infusion. (*p < 0.05 for paired t test statistic versus the heparin sample; {dagger}, p < 0.05 for paired t test statistic versus CPB perfusate sample.) (Reproduced from [6] with permission of Mosby, Inc.)

 
Monocytes express TF both in the wound and in the perfusion circuit and are strongly procoagulant. Expression of TF initiates the extrinsic coagulation pathway. Monocytes also produce numerous proinflammatory and antiinflammatory cytokines; the literature documents increases in interleukins IL-1, IL-2, IL-4, IL-6, IL-8, IL-10, and even IL-12, which acts as an inhibitor, during or after CPB. The literature is ambivalent about tumor necrosis factor, with nearly as many studies showing that it is not increased as there are showing that it is increased. Plasma concentrations of nearly all cytokines peak several hours after CPB [7]; thus, the impact of circulating cytokines is largely in the early postoperative period.


   Vasoactive substances associated with CPB
Top
 Abstract
 Introduction
 The contact system
 Complement
 Neutrophil activation
 Monocytes
 Vasoactive substances associated...
Inhibiting the inflammatory...
 References
 
A vasoactive substance may be defined as any substance that causes vascular smooth muscle to contract or relax, that causes an endothelial cell to contract or relax, or that influences myocyte contractility [8]. Large numbers of vasoactive substances are produced or affected by CPB and open heart operation, and the list in Table 2 is only a partial one. These substances produce edema, decrease myocardial contractility, and change vascular resistance in various vascular beds. The net result is that Claude Bernard’s postulated homeostasis is supplanted by chaos. Additionally, the coagulation pathways, destruction of blood cells, the wound, and the heart-lung machine produce numerous emboli of fibrin, fat, platelets, leukocytes, aggregates of platelets and white cells, red cell debris, gas, foreign material, and spallated particles. Although emboli larger than 40 µm are removed by the arterial filter, the patient’s body is showered by many emboli smaller than 40 µm. As capillaries are only about 8 to 10 µm in diameter, these emboli obstruct small, diffusely distributed vascular beds that supply small numbers of cells. The damage is largely unnoticed: a few cells die in hundreds of locations throughout the entire body.


View this table:
[in this window]
[in a new window]
  		Table 2. Vasoactive Substances Altered During Cardiopulmonary Bypass

 
Widely distributed cell necrosis and the increase in capillary permeability increase interstitial fluid. Fluid balance also is disturbed by an increase in systemic venous pressure and decreased colloid osmotic pressure produced by hemodilution. Consequently, interstitial fluid is vastly increased in proportion to the magnitude and duration of the operation. Whereas a first-time revascularization procedure with a relatively short pump run and small wound does not elicit much of an inflammatory response, a fourth-time redo with a bad heart that involves multiple grafts or multiple valve procedures elicits a large inflammatory response.

Interestingly, no one has demonstrated an increase in intracellular fluid associated with CPB; the fluid increase is all extravascular or intravascular, and most of it is extravascular. This edema and multiple emboli produce dysfunction of virtually all organs, including the heart, lungs, kidneys, central nervous system, pancreas, and liver. Fortunately, the dysfunction is usually temporary, without detectable permanent effects. However, sophisticated neuropsychologic tests done 6 weeks, 6 months, and even 1 year postoperatively consistently show a detectable decrease in function in up to 60% of patients who have had an open heart operation [9].


   Inhibiting the inflammatory response
Top
 Abstract
 Introduction
 The contact system
 Complement
 Neutrophil activation
 Monocytes
 Vasoactive substances associated...
 Inhibiting the inflammatory...
References
 
A number of studies have shown that a heparin-bonded surface attenuates terminal complement complex formation during CPB [10]. Other studies have shown attenuation of myeloperoxidase and lactoferrin release by neutrophils [11]. In a clinical study we observed attenuation of neutrophil elastase release [12]. To some degree, heparin-coated surfaces of the perfusion circuit attenuate the inflammatory response to CPB but do not obliterate it. Whether this attenuation is sufficient to justify the considerable expense remains to be resolved.

In a study at Boston University, Aldea and associates [12] used a heparin-coated perfusion circuit and half-dose systemic heparin in a large number of first-time revascularization patients. Half-dose systemic heparin with activated clotting times less than 300 seconds is dangerous because increased thrombin is produced and circulated. Thrombin is a dangerous enzyme to circulate; it has many actions. These patients did well, however, because the surgeons did not return blood aspirated from the wound to the perfusate. All blood aspirated from the wound was put into the cell-saving device, washed, and returned as packed red cells to the circulation. This substantially reduced the amount of thrombin added to the perfusate from the wound. The study convincingly showed a reduction in the inflammatory response using these clinical perfusion circuits. Aldea and colleagues [12] observed reductions in ventilatory requirements, hospital stays, and other benefits.

It has been suggested that low-dose aprotinin reduces the inflammatory response. In my view, any effect of aprotinin on the inflammatory response is probably very small. Aprotinin inhibits both plasmin and kallikrein, but the inhibitor dose for kallikrein is 100 times greater than that for plasmin. Thus, 100 times more aprotinin is required to inhibit kallikrein than to inhibit fibrinolysis. High doses of aprotinin may attenuate some of the inflammatory response, but the drug is not potent enough to have much impact.

Considerable research is under way on the antiinflammatory effects of protease inhibitors during CPB. At present nafamostat is the most promising among the six or seven protease inhibitors that we have evaluated [13]. During in vitro recirculation of fresh heparinized human blood, nafamostat completely inhibited kallikrein, factor XIIa formation, and neutrophil elastase release, but did not inhibit complement activation. Although complement activates neutrophils, the fact that elastase release was inhibited underscores the fact that neutrophils are activated by many substances other than complement. These include kallikrein, platelets, neutrophil-activating proteins 1 and 2, and cathepsin.

Eventually, we will probably be more successful in inhibiting the inflammatory response of CPB with protease inhibitors than with circuit-surface coatings. Protease inhibitors are abundant and are likely to be more effective, more specific, and cheaper than surface coatings. As increasing numbers of investigators address the effects of protease inhibitors on the inflammatory response, drugs that temporarily shut down activation of the four main blood components involved will be found. This will make open heart operations essentially comparable to surgical procedures done without the heart-lung machine.


   References
Top
 Abstract
 Introduction
 The contact system
 Complement
 Neutrophil activation
 Monocytes
 Vasoactive substances associated...
 Inhibiting the inflammatory...
 References
 

  1. Edmunds L.H., Jr Extracorporeal perfusion. In: Edmunds L.H., Jr, ed. Cardiac surgery in the adult. New York: McGraw-Hill, 1997:255-294.
  2. Colman R.W. Surface-mediated defense reactions. The plasma contact activation system. J Clin Invest 1984;73:1249-1253.
  3. Craddock P.R., Fehr J., Brigham K.L., Kronenberg R.S., Jacob H.S. Complement and leukocyte-mediated pulmonary dysfunction in hemodialysis. N Engl J Med 1977;296:769-774.[Abstract]
  4. Kappelmayer J., Bertiabei A., Edmunds L.H., Jr, Edginton T.S., Colman R.W. Tissue factor is expressed on monocytes during simulated extracorporeal circulation. Circ Res 1993;72:1075-1081.[Abstract/Free Full Text]
  5. Chung J.H., Gikakis N., Drake T.A., et al. Pericardial blood activates the extrinsic coagulation pathway during clinical cardiopulmonary bypass. Circulation 1996;93:2014-2018.[Abstract/Free Full Text]
  6. Steinberg J.B., Kapelanski D.P., Olson J.D., Weller J.M. Cytokine and complement levels in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 1993;106:1008-1016.[Abstract]
  7. Downing S.W., Edmunds L.H., Jr Release of vasoactive substances during cardiopulmonary bypass. Ann Thorac Surg 1992;54:1236-1243.[Abstract]
  8. Hammon J.W., Jr, Stump D.A., Kon N.D., Harrison M., Newman S.P., Treasure T. Risk factors and solutions for the development of neurobehavioral changes after coronary artery bypass grafting. Ann Thorac Surg 1997;63:1613-1618.[Abstract/Free Full Text]
  9. Videm V., Svennevig J.L., Fosse E., et al. Reduced complement activation with heparin-coated oxygenator and tubings in coronary bypass operations. J Thorac Cardiovasc Surg 1992;103:806-813.[Abstract]
  10. Borowiec J., Thelin S., Bagge L., et al. Decreased blood loss after cardiopulmonary bypass using heparin-coated circuit and 50% reduction of heparin dose. Scand J Thorac Cardiovasc Surg 1992;26:177-185.[Medline]
  11. Gorman R.C., Ziats N.P., Gikakis N., et al. Surface-bound heparin fails to reduce thrombin formation during clinical cardiopulmonary bypass. J Thorac Cardiovasc Surg 1996;111:1-12.[Abstract/Free Full Text]
  12. Aldea G.S., Doursounian M., O’Gara P., et al. Heparin-bonded circuits with a reduced anticoagulation protocol in primary CABG: a prospective, randomized study. Ann Thorac Surg 1996;62:410-418.[Abstract/Free Full Text]
  13. Sundaram S., Gikakis N., Hack C.E., et al. Nafamostat mesilate, a broad spectrum protease inhibitor, modulates platelet, neutrophil and contact activation in simulated extracorporeal circulation. Thromb Haemost 1996;75:76-82.[Medline]



This article has been cited by other articles:


Home page
 Eur Heart JHome page
N. Girerd, P. Pibarot, D. Fournier, P. Daleau, P. Voisine, G. O'Hara, J.-P. Despres, and P. Mathieu
Middle-aged men with increased waist circumference and elevated C-reactive protein level are at higher risk for postoperative atrial fibrillation following coronary artery bypass grafting surgery
Eur. Heart J., May 2, 2009; 30(10): 1270 - 1278.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
W.-J. P. van Boven, W. B. Gerritsen, A. H. Driessen, W. J. Morshuis, F. G. Waanders, F. J. Haas, E. P. van Dongen, and L. P. Aarts
Myocardial oxidative stress, and cell injury comparing three different techniques for coronary artery bypass grafting
Eur. J. Cardiothorac. Surg., November 1, 2008; 34(5): 969 - 975.
[Abstract] [Full Text] [PDF]

Home page
 Asian Cardiovasc. Thorac. Ann.Home page
S. G Raja and G. D Dreyfus
Current Status of Off-pump Coronary Artery Bypass Surgery
Asian Cardiovasc Thorac Ann, April 1, 2008; 16(2): 164 - 178.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
R. Eggum, T. Ueland, T. E. Mollnes, V. Videm, P. Aukrust, A. E. Fiane, and H. L. Lindberg
Effect of Perfusion Temperature on the Inflammatory Response During Pediatric Cardiac Surgery
Ann. Thorac. Surg., February 1, 2008; 85(2): 611 - 617.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
J. Feng and F. W. Sellke
Invited commentary
Ann. Thorac. Surg., January 1, 2008; 85(1): 87 - 88.
[Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
A. Radaelli, C. Loardi, M. Cazzaniga, G. Balestri, C. DeCarlini, M. G. Cerrito, E. N. Cusa, L. Guerra, S. Garducci, D. Santo, et al.
Inflammatory Activation During Coronary Artery Surgery and Its Dose-Dependent Modulation by Statin/ACE-Inhibitor Combination
Arterioscler. Thromb. Vasc. Biol., December 1, 2007; 27(12): 2750 - 2755.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
A. A. Amirghofran and A. Emami Nia
Right Heart Operations Without Cardiopulmonary Bypass: The Use of Temporary Total Cavopulmonary Connection
Ann. Thorac. Surg., October 1, 2007; 84(4): 1414 - 1415.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
N. Echahidi, D. Mohty, P. Pibarot, J.-P. Despres, G. O'Hara, J. Champagne, F. Philippon, P. Daleau, P. Voisine, and P. Mathieu
Obesity and Metabolic Syndrome Are Independent Risk Factors for Atrial Fibrillation After Coronary Artery Bypass Graft Surgery
Circulation, September 11, 2007; 116(11_suppl): I-213 - I-219.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
N. Echahidi, P. Pibarot, J.-P. Despres, J.-M. Daigle, D. Mohty, P. Voisine, R. Baillot, and P. Mathieu
Metabolic Syndrome Increases Operative Mortality in Patients Undergoing Coronary Artery Bypass Grafting Surgery
J. Am. Coll. Cardiol., August 28, 2007; 50(9): 843 - 851.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
O. Warren, C. Alexiou, R. Massey, D. Leff, S. Purkayastha, J. Kinross, A. Darzi, and T. Athanasiou
The effects of various leukocyte filtration strategies in cardiac surgery
Eur. J. Cardiothorac. Surg., April 1, 2007; 31(4): 665 - 676.
[Abstract] [Full Text] [PDF]

Home page
 Clin TrialsHome page
D. Novitzky, A L. Shroyer, J. F Collins, G. O McDonald, J. Lucke, B. Hattler, E. Kozora, D. D Bradham, J. Baltz, F. L Grover, et al.
A study design to assess the safety and efficacy of on-pump versus off-pump coronary bypass grafting: the ROOBY trial
Clinical Trials, February 1, 2007; 4(1): 81 - 91.
[Abstract] [PDF]

Home page
 Ann. Thorac. Surg.Home page
C. S. Rinder, M. J. Smith, H. M. Rinder, D. N. Cortright, R. M. Brodbeck, J. E. Krause, and B. R. Smith
Leukocyte Effects of C5a-Receptor Blockade During Simulated Extracorporeal Circulation
Ann. Thorac. Surg., January 1, 2007; 83(1): 146 - 152.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
L.-M. Stevens, S. Fortier, M.-C. Aubin, I. El-Hamamsy, S. Maltais, M. Carrier, and L. P. Perrault
Effect of tetrahydrobiopterin on selective endothelial dysfunction of epicardial porcine coronary arteries induced by cardiopulmonary bypass.
Eur. J. Cardiothorac. Surg., September 1, 2006; 30(3): 464 - 471.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
X. Dong, Y. Liu, M. Du, Q. Wang, C. T. Yu, and X. Fan
P38 mitogen-activated protein kinase inhibition attenuates pulmonary inflammatory response in a rat cardiopulmonary bypass model.
Eur. J. Cardiothorac. Surg., July 1, 2006; 30(1): 77 - 84.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
K. Wiebe, H. Baraki, P. Macchiarini, and A. Haverich
Extended pulmonary resections of advanced thoracic malignancies with support of cardiopulmonary bypass
Eur. J. Cardiothorac. Surg., April 1, 2006; 29(4): 571 - 577.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
J. M. Schultz, T. Karamlou, J. Swanson, I. Shen, and R. M. Ungerleider
Hypothermic Low-Flow Cardiopulmonary Bypass Impairs Pulmonary and Right Ventricular Function More Than Circulatory Arrest
Ann. Thorac. Surg., February 1, 2006; 81(2): 474 - 480.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
V. Cavalca, E. Sisillo, F. Veglia, E. Tremoli, G. Cighetti, L. Salvi, A. Sola, L. Mussoni, P. Biglioli, G. Folco, et al.
Isoprostanes and Oxidative Stress in Off-Pump and On-Pump Coronary Bypass Surgery
Ann. Thorac. Surg., February 1, 2006; 81(2): 562 - 567.
[Abstract] [Full Text] [PDF]

Home page
 PerfusionHome page
D. C Whitaker, J. Stygall, M. J. Harrison, I. J Mackie, M. Kemp, J. Hooper, W. B Pugsley, and S. P Newman
Leucocyte-depleting arterial line filtration does not reduce myocardial injury assessed by Troponin T during routine coronary artery bypass grafting using crossclamp fibrillation
Perfusion, January 1, 2006; 21(1): 55 - 60.
[Abstract] [PDF]

Home page
 HeartHome page
J Cosgrave, J B Foley, R Kelly, E McGovern, K Bennett, V Young, M Tolan, P Crean, D Kelleher, and M J Walsh
Perioperative serum inflammatory response and the development of atrial fibrillation after coronary artery bypass surgery
Heart, November 1, 2005; 91(11): 1475 - 1476.
[Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
S. R. Leal-Noval, R. Amaya, A. Herruzo, A. Hernandez, A. Ordonez, A. Marin-Niebla, and P. Camacho
Effects of a Leukocyte Depleting Arterial Line Filter on Perioperative Morbidity in Patients Undergoing Cardiac Surgery: A Controlled Randomized Trial
Ann. Thorac. Surg., October 1, 2005; 80(4): 1394 - 1400.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
E. Fung, R. R. Fiscus, A. P. C. Yim, G. D. Angelini, and A. A. Arifi
The Potential Use of Type-5 Phosphodiesterase Inhibitors in Coronary Artery Bypass Graft Surgery
Chest, October 1, 2005; 128(4): 3065 - 3073.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
K. Matsuzaki, Y. Hiramatsu, S. Homma, S. Sato, O. Shigeta, and Y. Sakakibara
Sivelestat Reduces Inflammatory Mediators and Preserves Neutrophil Deformability During Simulated Extracorporeal Circulation
Ann. Thorac. Surg., August 1, 2005; 80(2): 611 - 617.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
C. P. Cannon, S. R. Mehta, and S. F. Aranki
Balancing the Benefit and Risk of Oral Antiplatelet Agents in Coronary Artery Bypass Surgery
Ann. Thorac. Surg., August 1, 2005; 80(2): 768 - 779.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
A. Parolari, L. Mussoni, M. Frigerio, M. Naliato, F. Alamanni, A. Galanti, G. Fiore, F. Veglia, E. Tremoli, P. Biglioli, et al.
Increased prothrombotic state lasting as long as one month after on-pump and off-pump coronary surgery
J. Thorac. Cardiovasc. Surg., August 1, 2005; 130(2): 303 - 308.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
Y. Sato, Y. Hiramatsu, S. Homma, M. Sato, S. Sato, S. Endo, and Y. Sohara
Phosphodiesterase type 4 inhibitor rolipram inhibits activation of monocytes during extracorporeal circulation
J. Thorac. Cardiovasc. Surg., August 1, 2005; 130(2): 346 - 350.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
M. L. Fontes, J. P. Mathew, H. M. Rinder, D. Zelterman, B. R. Smith, C. S. Rinder, and the Multicenter Study of Perioperative Ischemia (M
Atrial Fibrillation After Cardiac Surgery/Cardiopulmonary Bypass Is Associated with Monocyte Activation
Anesth. Analg., July 1, 2005; 101(1): 17 - 23.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
E. A. Williams, R. J. Ing, J. P. Hart, J. Jaggers, F. H. Kern, D. M. Craig, and S. V. Pizzo
Soluble {alpha}2-macroglobulin receptor is increased in endotracheal aspirates from infants and children after cardiopulmonary bypass
J. Thorac. Cardiovasc. Surg., May 1, 2005; 129(5): 1098 - 1103.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
Y. Hiramatsu, S. Homma, Y. Sato, S. Sato, K. Matsuzaki, O. Shigeta, and Y. Sakakibara
Nafamostat Preserves Neutrophil Deformability and Reduces Microaggregate Formation During Simulated Extracorporeal Circulation
Ann. Thorac. Surg., April 1, 2005; 79(4): 1326 - 1332.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
K. T. Lappegard, J. Riesenfeld, O.-L. Brekke, G. Bergseth, J. D. Lambris, and T. E. Mollnes
Differential Effect of Heparin Coating and Complement Inhibition on Artificial Surface-Induced Eicosanoid Production
Ann. Thorac. Surg., March 1, 2005; 79(3): 917 - 923.
[Abstract] [Full Text] [PDF]

Home page
 PerfusionHome page
K. Cagli, M. M. Ulas, K. Ozisik, A. Kale, V. Bakuy, M. Emir, M. Balci, M. Topbas, E. Sener, and O. Tasdemir
The intraoperative effect of pentoxifylline on the inflammatory process and leukocytes in cardiac surgery patients undergoing cardiopulmonary bypass
Perfusion, January 1, 2005; 20(1): 45 - 51.
[Abstract] [PDF]

Home page
 Eur Heart JHome page
G. J Murphy, R. Ascione, and G. D Angelini
Coronary artery bypass grafting on the beating heart: surgical revascularization for the next decade?
Eur. Heart J., December 1, 2004; 25(23): 2077 - 2085.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
C. Alexiou, A. T.M. Tang, S. V. Sheppard, M. P. Haw, R. Gibbs, and D. C. Smith
A Prospective Randomized Study to Evaluate the Effect of Leukodepletion on the Rate of Alveolar Production of Exhaled Nitric Oxide During Cardiopulmonary Bypass
Ann. Thorac. Surg., December 1, 2004; 78(6): 2139 - 2145.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
M. Ruel, T. A. Khan, P. Voisine, C. Bianchi, and F. W. Sellke
Vasomotor dysfunction after cardiac surgery
Eur. J. Cardiothorac. Surg., November 1, 2004; 26(5): 1002 - 1014.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
N. D. Desai, M. P. Pelletier, H. R. Mallidi, G. T. Christakis, G. N. Cohen, S. E. Fremes, and B. S. Goldman
Why Is Off-Pump Coronary Surgery Uncommon in Canada? Results of a Population-Based Survey of Canadian Heart Surgeons
Circulation, September 14, 2004; 110(11_suppl_1): II-7 - II-12.
[Abstract] [Full Text] [PDF]

Home page
 Am J Crit CareHome page
R. Wynne and M. Botti
Postoperative Pulmonary Dysfunction in Adults After Cardiac Surgery With Cardiopulmonary Bypass: Clinical Significance and Implications for Practice
Am. J. Crit. Care., September 1, 2004; 13(5): 384 - 393.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
P. A. Berdat, E. Eichenberger, J. Ebell, J.-P. Pfammatter, M. Pavlovic, C. Zobrist, E. Gygax, U. Nydegger, and T. Carrel
Elimination of proinflammatory cytokines in pediatric cardiac surgery: Analysis of ultrafiltration method and filter type
J. Thorac. Cardiovasc. Surg., June 1, 2004; 127(6): 1688 - 1696.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
J. D. Puskas, W. H. Williams, E. M. Mahoney, P. R. Huber, P. C. Block, P. G. Duke, J. R. Staples, K. E. Glas, J. J. Marshall, M. E. Leimbach, et al.
Off-Pump vs Conventional Coronary Artery Bypass Grafting: Early and 1-Year Graft Patency, Cost, and Quality-of-Life Outcomes: A Randomized Trial
JAMA, April 21, 2004; 291(15): 1841 - 1849.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
K. T. Lappegard, M. Fung, G. Bergseth, J. Riesenfeld, J. D. Lambris, V. Videm, and T. E. Mollnes
Effect of complement inhibition and heparin coating on artificial surface-induced leukocyte and platelet activation
Ann. Thorac. Surg., March 1, 2004; 77(3): 932 - 941.
[Abstract] [Full Text] [PDF]

Home page
 PerfusionHome page
S. Mirsadraee, A. Fraser, M. A Kerr, T. E James, and C. van Doorn
Inflammatory response in an immunosuppressed patient with Wegener's granulomatosis
Perfusion, March 1, 2004; 19(2): 127 - 131.
[Abstract] [PDF]

Home page
 Ann. Thorac. Surg.Home page
Y. Kaminishi, Y. Hiramatsu, Y. Watanabe, Y. Yoshimura, and Y. Sakakibara
Effects of nafamostat mesilate and minimal-dose aprotinin on blood-foreign surface interactions in cardiopulmonary bypass
Ann. Thorac. Surg., February 1, 2004; 77(2): 644 - 650.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
L. Wehlin, J. Vedin, J. Vaage, and J. Lundahl
Activation of complement and leukocyte receptors during on- and off pump coronary artery bypass surgery
Eur. J. Cardiothorac. Surg., January 1, 2004; 25(1): 35 - 42.
[Abstract] [Full Text] [PDF]

Home page
 ICVTSHome page
J. Vedin, U. Jensen, A. Ericsson, C. Bitkover, S. Samuelsson, F. Bredin, and J. Vaage
Cardiovascular function during the first 24 hours after off pump coronary artery bypass grafting-a prospective, randomized study
Interactive CardioVascular and Thoracic Surgery, December 1, 2003; 2(4): 489 - 494.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
Y. Yoshimura, Y. Hiramatsu, Y. Sato, S. Homma, Y. Enomoto, T. Jikuya, and Y. Sakakibara
ONO-6818, a novel, potent neutrophil elastase inhibitor, reduces inflammatory mediators during simulated extracorporeal circulation
Ann. Thorac. Surg., October 1, 2003; 76(4): 1234 - 1239.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
M. J. Magee, L. P. Coombs, E. D. Peterson, and M. J. Mack
Patient Selection and Current Practice Strategy for Off-pump Coronary Artery Bypass Surgery
Circulation, September 9, 2003; 108(90101): II-9 - 14.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
P. Biglioli, A. Cannata, F. Alamanni, M. Naliato, M. Porqueddu, M. Zanobini, E. Tremoli, and A. Parolari
Biological effects of off-pump vs. on-pump coronary artery surgery: focus on inflammation, hemostasis and oxidative stress
Eur. J. Cardiothorac. Surg., August 1, 2003; 24(2): 260 - 269.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
P. Giomarelli, S. Scolletta, E. Borrelli, and B. Biagioli
Myocardial and lung injury after cardiopulmonary bypass: role of interleukin (IL)-10
Ann. Thorac. Surg., July 1, 2003; 76(1): 117 - 123.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
D. Shum-Tim, C. I. Tchervenkov, E. Laliberte, A.-M. Jamal, T. Nimeh, C.-Y. Luo, B. Bittira, and A. Philip
Timing of steroid treatment is important for cerebral protection during cardiopulmonary bypass and circulatory arrest: minimal protection of pump prime methylprednisolone
Eur. J. Cardiothorac. Surg., July 1, 2003; 24(1): 125 - 132.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
M. L.K. Sheil, T. B. Cartmill, G. R. Nunn, G. F. Sholler, O. T. Raitakari, and D. S. Celermajer
Contrast echocardiography: potential for the in-vivo study of pediatric myocardial preservation
Ann. Thorac. Surg., May 1, 2003; 75(5): 1542 - 1548.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
Y. Yoshimura, Y. Hiramatsu, Y. Sato, S. Homma, Y. Enomoto, Y. Kikuchi, and Y. Sakakibara
Activated neutrophils and platelet microaggregates impede blood filterability through microchannels during simulated extracorporeal circulation
Ann. Thorac. Surg., April 1, 2003; 75(4): 1254 - 1260.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
C. S. Rinder, M. Fontes, J. P. Mathew, H. M. Rinder, and B. R. Smith
Neutrophil CD11b upregulation during cardiopulmonary bypass is associated with postoperative renal injury
Ann. Thorac. Surg., March 1, 2003; 75(3): 899 - 905.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
M. Ninomiya, K. Miyaji, and S. Takamoto
Influence of PMEA-coated bypass circuits on perioperative inflammatory response
Ann. Thorac. Surg., March 1, 2003; 75(3): 913 - 917.
[Abstract] [Full Text] [PDF]

Home page
 PerfusionHome page
W. Eichler, J F M. Bechtel, J. Schumacher, J. A Wermelt, K.-F. Klotz, and C. Bartels
A rise of MMP-2 and MMP-9 in bronchoalveolar lavage fluid is associated with acute lung injury after cardiopulmonary bypass in a swine model
Perfusion, March 1, 2003; 18(2): 107 - 113.
[Abstract] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
A. Parolari, S. Colli, L. Mussoni, S. Eligini, M. Naliato, X. Wang, S. Gandini, E. Tremoli, P. Biglioli, and F. Alamanni
Coagulation and fibrinolytic markers in a two-month follow-up of coronary bypass surgery
J. Thorac. Cardiovasc. Surg., February 1, 2003; 125(2): 336 - 343.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
R Ascione and G.D Angelini
OPCAB surgery: a voyage of discovery back to the future
Eur. Heart J., January 2, 2003; 24(2): 121 - 124.
[Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
R. Ascione, M. Caputo, and G. D. Angelini
Off-pump coronary artery bypass grafting: not a flash in the pan
Ann. Thorac. Surg., January 1, 2003; 75(1): 306 - 313.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
Y. Sato, Y. Hiramatsu, S. Homma, S. Sato, M. Onizuka, and Y. Sakakibara
Phosphodiesterase type 4 inhibition of activated polymorphonuclear leukocytes in a simulated extracorporeal circulation model
J. Thorac. Cardiovasc. Surg., January 1, 2003; 125(1): 172 - 177.
[Abstract] [Full Text]

Home page
 Card Surg AdultHome page
R. Salenger, J. S. Gammie, and T. J. Vander Salm
Postoperative Care of Cardiac Surgical Patients
Card. Surg. Adult, January 1, 2003; 2(2003): 439 - 469.
[Full Text]

Home page
 Ann. Thorac. Surg.Home page
H.-H Sievers, C. Freund-Kaas, S. Eleftheriadis, T. Fischer, H. Kuppe, E. G. Kraatz, and J.F. M. Bechtel
Lung protection during total cardiopulmonary bypass by isolated lung perfusion: preliminary results of a novel perfusion strategy
Ann. Thorac. Surg., October 1, 2002; 74(4): 1167 - 1172.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
P. Kessler, G. Neidhart, D. H. Bremerich, T. Aybek, S. Dogan, V. Lischke, and C. Byhahn
High Thoracic Epidural Anesthesia for Coronary Artery Bypass Grafting Using Two Different Surgical Approaches in Conscious Patients
Anesth. Analg., October 1, 2002; 95(4): 791 - 797.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
A. Undar, H. C. Eichstaedt, F. J. Clubb Jr, M. Fung, M. Lu, J. E. Bigley, W. K. Vaughn, and C. D. Fraser Jr
Novel anti-factor D monoclonal antibody inhibits complement and leukocyte activation in a baboon model of cardiopulmonary bypass
Ann. Thorac. Surg., August 1, 2002; 74(2): 355 - 362.
[Abstract] [Full Text] [PDF]

Home page
 PerfusionHome page
L H. Edmunds Jr
The evolution of cardiopulmonary bypass: lessons to be learned
Perfusion, July 1, 2002; 17(4): 243 - 251.
[Abstract] [PDF]

Home page
 PerfusionHome page
R. Ascione, S. Al-Ruzzeh, K. Amer, and G. D Angelini
Subsystem organ function during coronary surgery
Perfusion, July 1, 2002; 17(4): 295 - 303.
[Abstract] [PDF]

Home page
 PerfusionHome page
G. A Ortolano, G. S Aldea, K. Lilly, P. O'Gara, J. D Alkon, F. Madera, T. Murad, C. P Altenbern, C. S Tritt, A. Capetandes, et al.
A review of leukofiltration in cardiac surgery: the time course of reperfusion injury may facilitate study design of anti-inflammatory effects
Perfusion, March 1, 2002; 17(2_suppl): 53 - 62.
[Abstract] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
Y.-F. Chen, W.-C. Tsai, C.-C. Lin, C.-S. Lee, C.-H. Huang, P.-C. Pan, M.-L. Chen, and Y.-S. Huang
Leukocyte depletion attenuates expression of neutrophil adhesion molecules during cardiopulmonary bypass in human beings
J. Thorac. Cardiovasc. Surg., February 1, 2002; 123(2): 218 - 224.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
R. C. Landis, G. Asimakopoulos, M. Poullis, D. O. Haskard, and K. M. Taylor
The antithrombotic and antiinflammatory mechanisms of action of aprotinin
Ann. Thorac. Surg., December 1, 2001; 72(6): 2169 - 2175.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
N. Ellison and G. J. Despotis
Attenuating defects in hemostasis, inflammatory response, and neurologic outcomes: all are desirable goals
Ann. Thorac. Surg., November 1, 2001; 72(5): S1804 - 1805.
[Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
R. C. Landis, D. O. Haskard, and K. M. Taylor
New antiinflammatory and platelet-preserving effects of aprotinin
Ann. Thorac. Surg., November 1, 2001; 72(5): S1808 - 1813.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
J. C. Cleveland Jr, A. L. W. Shroyer, A. Y. Chen, E. Peterson, and F. L. Grover
Off-pump coronary artery bypass grafting decreases risk-adjusted mortality and morbidity
Ann. Thorac. Surg., October 1, 2001; 72(4): 1282 - 1289.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
D. A. Velez, C. D. Morris, J. M. Budde, S. Muraki, R. N. Otto, R. A. Guyton, and J. Vinten-Johansen
All-Blood (Miniplegia) Versus Dilute Cardioplegia in Experimental Surgical Revascularization of Evolving Infarction
Circulation, September 18, 2001; 104 (2009): I-296 - I-302.
[Abstract] [Full Text] [PDF]

Home page
 SEMIN CARDIOTHORAC VASC ANESTHHome page
K. Kottke-Marchant and S. Sapatnekar
Hemostatic Abnormalities in Cardiopulmonary Bypass: Pathophysiologic and Transfusion Considerations
Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2001; 5(3): 187 - 206.
[Abstract] [PDF]

Home page
 SEMIN CARDIOTHORAC VASC ANESTHHome page
H. A. Hennein
Inflammation After Cardiopulmonary Bypass: Therapy for the Postpump Syndrome
Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2001; 5(3): 236 - 255.
[Abstract] [PDF]

Home page
 PerfusionHome page
L.-C. Hsu
Heparin-coated cardiopulmonary bypass circuits: current status
Perfusion, September 1, 2001; 16(5): 417 - 428.
[Abstract] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
M. Fung, P. G. Loubser, A. Undar, M. Mueller, C. Sun, W. N. Sun, W. K. Vaughn, and C. D. Fraser Jr
Inhibition of complement, neutrophil, and platelet activation by an anti-factor D monoclonal antibody in simulated cardiopulmonary bypass circuits
J. Thorac. Cardiovasc. Surg., July 1, 2001; 122(1): 113 - 122.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
Y. Okazaki, K. Takarabe, J.-i. Murayama, E. Suenaga, K. Furukawa, K. Rikitake, M. Natsuaki, and T. Itoh
Coronary endothelial damage during off-pump CABG related to coronary-clamping and gas insufflation
Eur. J. Cardiothorac. Surg., June 1, 2001; 19(6): 834 - 839.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
R. Cartier and D. Robitaille
Thrombotic complications in beating heart operations
J. Thorac. Cardiovasc. Surg., May 1, 2001; 121(5): 920 - 922.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
C. Joffs, H. R. Gunasinghe, M. M. Multani, B. H. Dorman, J. M. Kratz, A. J. Crumbley III, F. A. Crawford Jr, and F. G. Spinale
Cardiopulmonary bypass induces the synthesis and release of matrix metalloproteinases
Ann. Thorac. Surg., May 1, 2001; 71(5): 1518 - 1523.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
H. Suhara, Y. Sawa, M. Nishimura, H. Oshiyama, K. Yokoyama, N. Saito, and H. Matsuda
Efficacy of a new coating material, PMEA, for cardiopulmonary bypass circuits in a porcine model
Ann. Thorac. Surg., May 1, 2001; 71(5): 1603 - 1608.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
J. M. Craver and C. P. Murrah
Elective intraaortic balloon counterpulsation for high-risk off-pump coronary artery bypass operations
Ann. Thorac. Surg., April 1, 2001; 71(4): 1220 - 1223.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
V. R. Conti
Pulmonary Injury After Cardiopulmonary Bypass
Chest, January 1, 2001; 119(1): 2 - 4.
[Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
Y. Okazaki, Z.-L. Cao, S. Ohtsubo, M. Hamada, K. Naito, K. Rikitake, M. Natsuaki, and T. Itoh
Leukocyte-depleted reperfusion after long cardioplegic arrest attenuates ischemia-reperfusion injury of the coronary endothelium and myocardium in rabbit hearts
Eur. J. Cardiothorac. Surg., July 1, 2000; 18(1): 90 - 97.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
R. Ascione, C. T. Lloyd, M. J. Underwood, A. A. Lotto, A. A. Pitsis, and G. D. Angelini
Inflammatory response after coronary revascularization with or without cardiopulmonary bypass
Ann. Thorac. Surg., April 1, 2000; 69(4): 1198 - 1204.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
R. Cartier, S. Brann, F. Dagenais, R. Martineau, and A. Couturier
SYSTEMATIC OFF-PUMP CORONARY ARTERY REVASCULARIZATION IN MULTIVESSEL DISEASE: EXPERIENCE OF THREE HUNDRED CASES
J. Thorac. Cardiovasc. Surg., February 1, 2000; 119(2): 221 - 229.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Edmunds, L. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Edmunds, L. H., Jr

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS